Japan’s Kyowa Kirin expands to Dubai Healthcare City

By Rahul Vaimal, Associate Editor
  • Follow author on
Dubai Healthcare City
Representational Image

Japan-based global specialty pharmaceutical company, Kyowa Kirin Co. Ltd is expanding its presence in the UAE with a regional representative office of its subsidiary Kyowa Kirin International PLC. 

The newly opened office which was inaugurated by Dr. Amin Hussein Al Amiri, Assistant Under-Secretary for Public Health Policy and Licensing Sector in the Ministry of Health and Prevention (MoHAP), is located in Dubai Healthcare City.

The new facility will bring the total number of scientific offices operating in the country to 78 as MoHAp hopes to touch 85 offices by the end of 2021.

The opening ceremony was attended by Akima Umezawa, Consul-General of Japan in Dubai; Toshifumi Mikayama, Ph.D., Director of the board, Senior Managing Executive Officer of Kyowa Kirin; Dr. Ramadan Al Balushi, CEO of Dubai Healthcare City; and Abdul Molik, Head of Global Markets for the company; as well as other senior officials from the MoHAP.

Speaking on the occasion, Dr. Al Amiri said, “The UAE continues to attract global pharmaceutical companies to run their operations for the region, thanks to the country’s strong and unique business infrastructure, which helped create a competitive business environment. The country’s regulatory facilities have also resulted in creating investment opportunities attractive to pharmaceutical companies. The new office would help stimulate more Japanese pharmaceutical companies to invest in the UAE and the region.” He noted that the global pharmaceutical companies operating in the UAE are providing medicines to about 41 countries form their logistics warehouses in Dubai.

Dr. Al Amiri stated that the Ministry of Health is committed to strengthening its partnerships with international pharmaceutical companies, driving innovation and bringing the latest innovative drug pipelines to patients in the UAE, and supporting the country’s pharmaceutical economics.

For his part, Mikayama said, “As a global pharmaceutical company, we have an important role and responsibility for saving the lives of patients and improving their life quality. The launch of Kyowa Kirin’s operations in the UAE reflects the global expansion strategy of the company, aiming to harness its capabilities to add a new value to sustainable growth. We are interested in investing in the UAE and the wider region and are keen to develop a strong partnership with the Ministry of Health through sharing expertise and innovations”.